Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
2期
已完成
NCT04205409
| 适应症 | Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma |
|---|
| 分期 | 2期 |
|---|
| 申办方 | University of Washington |
|---|
| 状态 | 已完成 |
|---|
| 受试者人数 | 20 人 |
|---|
| 干预（药物） | Nivolumab |
|---|
| 开始日期 | 2020年6月5日 |
|---|
| 完成日期 | 2024年9月20日 |
|---|
| 结果公布日 | 2025年11月3日 |
|---|
摘要
This phase II trial studies how well nivolumab works for the treatment of hematological malignancies that have come back (relapsed), does not respond (refractory), or is detectable after CAR T cell therapy. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Best Overall Response Rate (ORR)
Up to 1 year and 8 months · Participants
| Treatment (Nivolumab) | 3 Participants |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。